Skip to main content

Table 1 Multivariate analysis of progression-free survival for patients undergoing NACT

From: Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial

 

CR/PR (n = 227)

SD/PD (n = 91)

NACT (n = 318)

 

Adjust p-Value

Adjust OR (95%CI)

Adjust p-Value

Adjust OR (95%CI)

Adjust p-Value

Adjust OR (95%CI)

Age

\

\

0.308

0.967 (0.906, 1.032)

\

\

Hb

0.020

0.976 (0.957, 0.996)

\

\

0.121

0.987 (0.972, 1.003)

Plt

0.459

1.002 (0.997, 1.006)

\

\

0.357

1.002 (0.998, 1.005)

BMI

\

\

0.201

0.892 (0.749, 1.063)

0.568

0.971 (0.877, 1.075)

Tumor size

 before NACT

0.566

0.904 (0.642, 1.274)

\

\

0.923

0.987 (0.760, 1.282)

 after NACT

0.021

1.720 (1.085, 2.726)

\

\

0.281

1.119 (0.912, 1.372)

> 1/2 depth of cervical invasion

0.029

2.358 (1.092, 5.090)

0.108

2.751 (0.803, 9.180)

0.006

2.580 (1.310, 5.079)

LVSI

\

\

\

\

0.857

0.927 (0.409, 2.102)

Vagina involvement

\

\

\

\

0.679

1.393 (0.290, 6.690)

Uterus involvement

0.233

1.998 (0.641, 6.225)

\

\

0.627

1.306 (0.445, 3.838)

Lymph node metastasis

0.041

2.391 (1.038, 5.508)

\

\

0.310

1.478 (0.696, 3.140)

  1. Candidate variables with a p-value < 0.2 on univariate analysis of Cox proportional hazards regression were included in the multivariable model and “\” meant the corresponding factor was not included
  2. Abbreviations: OR Odds ratio, Hb Hemoglobin concentration, Plt Platelet concentration, BMI Body mass index, SCCA Squamous Cell Carcinoma Antigen, NACT Neoadjuvant chemotherapy, LVSI lymphovascular space invasions
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us